Publikationen
Publikationen
(1997 - 2014)
Veröffentlichungen
| 1. | Kuckländer U., Hilgeroth A.: Versuche zur Darstellung N-substituierter Dihydrpyridine nach Hantzsch. Arch. Pharm. (Weinheim), 327, 287-294 (1994). |
| 2. | Hilgeroth A.: Solid-state Synthesis of Novel 3,9-Diazatetraasteranes. Chem. Letters, 1269-1270 (1997). |
| 3. | Hilgeroth A., Baumeister U., Heinemann F. W.: Novel Solid-State Synthesis of Polyfunctionalized 3,9-Diazatetraasteranes. Eur. J. Org. Chem., 1213-1218 (1998). |
| 4. | Hilgeroth A., Heinemann F. W.: Novel solid-state synthesis of dimeric 4-aryl-1,4-dihydropyridines. J. Heterocyclic Chem., 35, 359-364 (1998). |
| 5. | Hilgeroth A., Kuna K., Kuckländer U.: Novel Functionalized 1,4,4a,9a-Tetrahydro-1-aza-9-oxafluorenes by Cycloaddition of 4-(4-Methoxyphenyl)-1,4-dihydropyridines and p-Benzoquinone, als Communication. J. Heterocyclic Chem., 35, 551-553 (1998). |
| 6. | Hilgeroth A., Kuna K., Kuckländer U.: Novel Synthesis Of Polyfunctionalized 1,4,4a,9a-Tetrahydro-1-aza-9-oxafluorenes By Unexpected Cycloaddition Of 4-(4-Methoxyphenyl)-1,4-dihydropyridines and p-Benzoquinone. Heterocycles, 48, 1649-1658 (1998). |
| 7. | Hilgeroth A.: HIV-1 Protease-Inhibitoren im Überblick. Pharm. Uns. Zeit, 27, 22-25 (1998). |
| 8. | Hilgeroth A.: Neue Nucleosidanaloga in der Therapie viraler Erkrankungen im Überblick. Pharm. Uns. Zeit, 27, 111-116 (1998). |
| 9. | Hilgeroth A.: Neue dimere 1,4-Dihydropyridine. Deutsches Patent DE 197 56 881 (1998). |
| 10. | Hilgeroth A., Billich A.: Cage Dimeric 4-Aryl-1,4-dihydropyridines as Promising Lead Structures for the Development of a Novel Class of HIV-1 Protease Inhibitors. Arch. Pharm. Pharm. Med. Chem., 332, 3-5 (1999). |
| 11. | Hilgeroth A.: Neue Zytostatika im Überblick. Pharm. Uns. Zeit, 28, 309-313 (1999). |
| 12. | Hilgeroth A., Baumeister U., Heinemann F. W.: Topochemical investigations of dimerizing 4-aryl-1,4-dihydropyridines by X-ray crystal structure analysis. J. Mol. Structure, 474, 267-274 (1999). |
| 13. | Hilgeroth A., Fleischer R., Wiese M., Heinemann F. W.: Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: A molecular modeling study. J. Comput.-Aided Mol. Design, 13, 233-242 (1999). |
| 14. | Hilgeroth A., Hempel G., Baumeister U., Reichert D.: Solid-state photodimerization of 4-aryl-1,4-dihydropyridines studied by 13CPMAS NMR spectroscopy. Solid State Nucl. Mag. Res., 13, 231-243 (1999). |
| 15. | Hilgeroth A., Hempel G., Baumeister U., Reichert D.: Solid-state formation of centrosymmetric cage dimeric 4-aryl-1,4-dihydroypridines via non-symmetric syn-dimers studied by 13C cross-polarization magic angle spinning NMR spectroscopy. Magn. Reson. Chem., 37, 376-381 (1999). |
| 16. | Hilgeroth A., Baumeister U., Heinemann F. W.: Rotameric Properties Of Novel N-Acyl- and N-Acyloxy-Dimeric 4-Phenyl-1,4-dihydropyridines Derived From Developed Solid-State Synthesis. Heterocycles, 51, 2367-2376 (1999). |
| 17. | Hilgeroth A., Billich A.: Cage Dimeric N-Acyl- and N-Acyloxy-4-aryl-1,4-dihydropyridines as First Representatives of a Novel Class of HIV-1 Protease Inhibitors. Arch. Pharm. Pharm. Med. Chem., 332, 380-384 (1999). |
| 18. | Hilgeroth A., Wiese M., Billich A.: Synthesis and Biological Evaluation of First N-Alkyl Cage Dimeric 4-Aryl-1,4-dihydropyridines as Novel Nonpeptidic HIV-1 Protease Inhibitors. J. Med. Chem., 42, 4729-4732 (1999). |
| 19. | Hilgeroth A., Langner A.: First Bioanalytical Evaluation of Nonpeptidic Cage Dimeric HIV-1 Protease Inhibitor N-Benzyl 4-Aryl-1,4-dihydropyridine H17: Biotransformation and Toxicity on Hep G2 Cells. Arch. Pharm. Pharm. Med. Chem., 333, 32-34 (2000). |
| 20. | Hilgeroth A., Baumeister U., Heinemann F. W.: Solution-Dimerization of 4-Aryl-1,4-dihydropyridines. Eur. J. Org. Chem., 245-249 (2000). |
| 21. | Hilgeroth A.: Interaktionen als Schwerpunkt in der Pharmazeutischen Chemie. Pharm. Ztg., 145, 100 (2000). |
| 22. | Hilgeroth A., Baumeister U.: Erste funktionalisierte 6,12-Diazatetrakishomocubane. Angew. Chem., 112, 588-590 (2000). The First Functionalized 6,12-Diazatetrakishomocubanes. Angew. Chem. Int. Ed., 39, 576-578 (2000). |
| 23. | Hilgeroth A., Langner A.: Bioanalysis of Syn-dimeric N-Benzyl 4-Aryl-1,4-dihydropyridine H19: Metabolic and Cytotoxic Properties in Hep G2 Cells. Arch. Pharm. Pharm. Med. Chem., 333, 195-197 (2000). |
| 24. | Hilgeroth A., Langner A.: Plasma Protein Binding Properties of Dimeric 4-Aryl-1,4-dihydropyridines as Novel Nonpeptidic HIV-1 Protease Inhibitors. Pharmazie, 55, 542-543 (2000). |
| 25. | Hilgeroth A., Dressler C., Neuhoff S., Langguth P., Spahn-Langguth H.: Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors - affinities to intestinal P-glycoprotein. Pharmazie, 55, 784-785 (2000). |
| 26. | Hilgeroth A., Brachwitz K., Baumeister U.: Regioselective Formation Of Novel Functionalized 1-Aza-9-oxafluorenes. Heterocycles, 55, 661-669 (2001). |
| 27. | Hilgeroth A., Wollmann J.: HIV-Forschung - In der dritten Dekade einer Odyssee. Pharm. Ztg., 146, 2632-2636 (2001). |
| 28. | Hilgeroth A.: Neue Molekülklassen von HIV-1 Proteaseinhibitoren? Pharm. Uns. Zeit, 30, 213-216 (2001). |
| 29. | Hilgeroth A., Billich A., Lilie H.: Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors. Eur. J. Med. Chem., 36, 367-374 (2001). |
| 30. | Hilgeroth A., Baumeister U.: Formation of Novel Photodimers from 4-Aryl-1,4-dihydropyridines. Chem. Eur. J., 7, 4599-4603 (2001). |
| 31. | Brachwitz K., Hilgeroth A.: Synthesis and First Biological Evaluation of 1-Aza-9-oxafluorenes as Novel Lead Structures for the Development of Small-sized Cytostatics. Biorg. Med. Chem. Lett., 12, 411-413 (2002). |
| 32. | Hilgeroth A., Tykarska E., Jaskolski M.: Crystal structure of a novel synthetic inhibitor of HIV-1 protease. J. Mol. Structure, 605, 63-70 (2002). |
| 33. | Hilgeroth A., Heinemann F. W., Baumeister U.: First Rotameric Anti Dimers and 3,9-Diazatetraasteranes From Unsymmetrically Substituted N-Acyl and N-Acyloxy-4-aryl-1,4-dihydropyridines. Heterocycles, 57, 1003-1016 (2002). |
| 34. | Hilgeroth A.: Dimeric 4-Aryl-1,4-dihydropyridines: Development of a Third Class of Nonpeptidic HIV-1 Protease Inhibitors. Min. Rev. Med. Chem., 2, 235-247 (2002). |
| 35. | Hilgeroth A., Molnár J., De Clercq E.: Mit molekularer Symmetrie zu neuen Wirkstoffen: Hydroxymethyl-substituierte 3,9-Diazatetraasterane als erste eigenständige Klasse symmetrischer MDR-Modulatoren, Angew. Chem., 114, 3772-3775 (2002). Using Molecular Symmetry to Form New Drugs: Hydroxymethyl-substituted 3,9-Diazatetraasteranes as the First Class of Symmetric MDR Modulators. Angew. Chem. Int. Ed., 41, 3623-3625 (2002). |
| 36. | Brachwitz K., Voigt B., Meijer L., Lozach O., Schächtele C., Molnár J., Hilgeroth A.: Evaluation of The First Cytostatically Active 1-Aza-9-oxafluorenes as Novel Selective CDK1-Inhibitors with P-Glycoprotein Modulating Properties. J. Med. Chem., 46, 876-879 (2003). |
| 37. | Hilgeroth A., Lilie H.: Structure-activity relationships of first bishydroxymethyl-substituted cage dimeric 4-aryl-1,4-dihydropyridines as HIV-1 protease inhibitors. Eur. J. Med. Chem., 38, 495-499 (2003). |
| 38. | Voigt B., Hilgeroth A.: 3-Hydroquinolyl-quinolines and Bisquinolyl-anelated Oxepin as Reaction Products From p-Benzoquinone and N-Acetyl-1,4-dihydroquinolines. Heterocycles, 60, 2223-2230 (2003). |
| 39. | Richter M., Gyémánt N., Molnár J., Hilgeroth A.: Comparative Effects on Intestinal Absorption in Situ by P-Glycoprotein Modifying HIV Protease Inhibitors. Pharm. Res., 21, 1862-1866 (2004). |
| 40. | Voigt B., Meijer L., Lozach O., Schächtele C., Totzke F., Hilgeroth A.: Novel CDK-Inhibition Profiles of Structurally Varied 1-Aza-9-oxafluorenes. Bioorg. Med. Chem. Letters, 15, 823-825 (2005). |
| 41. | Sharples D., Spengler G., Molnár J, Antal Z., Molnár A., Kiss J., Szabó A., Hilgeroth A., Gallo S., Mahamoud A., Barbe J.: The interaction between resistance modifiers such as pyrido[3,2-g]quinoline, azafluorene and pregnane derivatives with DNA, plasmid DNA and tRNA. Eur. J. Med. Chem., 40, 195-202 (2005). |
| 42. | Wollmann J., Baumeister U., Hilgeroth A.: Topochemical characterization of photostable 4-hydroxyaryl-1,4-dihydropyridines by X-ray crystal structure analysis. J. Mol. Structure, 743, 169-175 (2005). |
| 43. | Wollmann J., Richter M., Molnár J., Hilgeroth A.: First Insight in Symmetry and Flexibilty of Membrane Efflux Pump P-glycoprotein by Novel Bifunctional Modulators. ChemBioChem., 8, 1353-1356 (2005). |
| 44. | Hilgeroth A., Molnár A., Molnár J., Voigt B.: Correlation of Calculated Molecular Orbital Energies of Some Phenothiazine Compounds with MDR-Reversing Properties. Eur. J. Med. Chem., 41, 548-551 (2006). |
| 45. | Richter M., Molnár J., Hilgeroth A.: Biological Evaluation of Bishydroxymethyl Substituted Cage Dimeric 1,4-Dihydroypyridines as Novel Class of P-Glycoprotein Modulating Agents in Cancer Cells. J. Med. Chem., 49, 2838-2840 (2006). |
| 46. | Hilgeroth A.: Neue bifunktionale dimere 1,4-Dihydropyridine. Deutsches Patent DE 10/2004/037/885 (2006). |
| 47. | Hilgeroth A.: Neue gemischte dimere 1,4-Dihydropyridine. Deutsches Patent DE 10/2004/037/911 (2006). |
| 48. | Wollmann J., Molnár J., Hilgeroth A.: Physicochemical Characteristics Of Novel P-Glycoprotein Inhibitors Of The Cage Dimeric 1,4-Dihydropyridine Type. Med. Chem., 2, 565-568 (2006). |
| 49. | Richter M., Gyémánt N., Molnár J., Hilgeroth A.: P-Glycoprotein Effects of Cyclic Urea HIV Protease Inhibitor DMP 323 in Competitional Absorption Studies. Arch. Pharm. Chem. Life Sci., 339, 625-628 (2006). |
| 50. | Wollmann J., Hilgeroth A.: Antiretrovirale Therapie: Neue Ansätze im Kampf gegen HIV. Pharm. Ztg., 151, 4496-4503 (2006). |
| 51. | Voigt B., Coburger C., Molnár J., Hilgeroth A.: Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as P-glycoprotein inhibitors. Bioorg. Med. Chem., 15, 5110-5113 (2007). |
| 52. | Voigt B., Krug M., Schächtele C., Totzke F., Hilgeroth A.: Probing Novel 1-Aza-9-oxafluorenes as Selective GSK-3ß Inhibitors. ChemMedChem, 3, 120-126 (2008). |
| 53. | Wollmann J., Baumert C., Erlenkamp G., Sippl W., Hilgeroth A.: Novel Insight in Inhibitor Binding of Highly Symmetric HIV-1 Protease. ChemBioChem, 9, 874-878 (2008). |
| 54. | Coburger C., Wollmann J., Baumert C., Krug M., Molnár J., Hilgeroth A.: Novel Insight in SAR and Bioanalysis of P-Glycoprotein Targeting Highly Potent Tetrakishydroxymethyl Substituted 3,9-Diazatetrasteranes. J. Med. Chem., 51, 5871-5874 (2008). |
| 55. | Duarte N., Járdánházy A., Molnár J., Hilgeroth A., Ferreira M.-J. U.: Synergistic interaction between p-glycoprotein modulators and epirubicin on resistant cancer cells. Bioorg. Med. Chem., 16, 9323-9330 (2008). |
| 56. | Krug M., Hilgeroth A.: Recent Advances in the Development of Multi-Kinase Inhibitors. Min. Rev. Med. Chem., 8, 1312-1327 (2008). |
| 57. | Richter M., Richter A., Langner A., Hilgeroth A.: Evaluation of substrate and inhibitor properties of a novel MDR modulator H17 towards transmembrane efflux pumps. Eur. J. Med. Chem., 44, 3060-3063 (2009). |
| 58. | Coburger C., Lage H., Molnár J., Hilgeroth A.: Impact of Novel MDR Modulators on Human Cancer Cells: Activities and Induction Studies. Pharm. Res., 26, 182-187 (2009). |
| 59. | Baumert C., Hilgeroth A.: Recent Advances in the Development of P-gp Inhibitors. Anti-Cancer Agents Med. Chem., 9, 415-436 (2009). |
| 60. | Lage H., Duarte N., Coburger C., Hilgeroth A., Ferreira M.-J. U.: Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells. Phytomedicine, 17, 441-448 (2010). |
| 61. | Krug M., Voigt B., Baumert C., Lüpken R., Molnár J., Hilgeroth A.: First Biological Evaluation of Developed 3-Benzyloxyfluorenes as Novel Class of MDR Modulators. Eur. J. Med. Chem., 45, 2683-2688 (2010). |
| 62. | Coburger C., Lage H., Molnár J., Langner A., Hilgeroth A.: MDR reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors. J. Pharm. Pharmacol., 62, 1704-1710 (2010). |
| 63. | Coburger C., Wollmann J., Krug M., Baumert C., Seifert M., Molnár J., Lage H., Hilgeroth A.: Novel structure-activity relationships and selectivity profiling of novel cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators. Bioorg. Med. Chem., 18, 4983-4990 (2010). |
| 64. | Krug M., Erlenkamp G., Sippl W., Schächtele C., Totzke F., Hilgeroth A.: Discovery and selectivity profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors, Bioorg. Med. Chem. Letters, 20, 6915-6919 (2010). |
| 65. | Krawczyk S., Coburger C., Hilgeroth A.: HIV-Infektion: Hoffnung auf neue Therapien, Pharm. Ztg., 155, 3999-4107 (2010). |
| 66. | Krug M., Wichapong K., Erlenkamp G., Sippl W., Schächtele C., Totzke F., Hilgeroth A.: Discovery of 4-Benzylamino Substituted α-Carbolines as a Novel Class of Receptor Tyrosine Kinase Inhibitors, ChemMedChem, 6, 63-72 (2011). |
| 67. | Telep El-Sayed M., Abbas M., Hilgeroth A.: Efficient One-Pot Formation of Substituted γ-Amino Acids, Letters Org. Chem., 8, 320-324 (2011) |
| 68. | Tell V., Hilgeroth A.: Alzheimer Demenz: Neue Arzneistoffe, neue Hoffnung?, Pharm. Ztg., 156, 3900-3906 (2011). |
| 69. | Krawczyk S., Otto M., Otto A., Coburger C., Krug M., Seifert M., Tell V., Molnár J., Hilgeroth A.: Discovery of pyridine-2-ones as novel class of multidrug resistance (MDR) modulators: First structure-activity relationships, Bioorg. Med. Chem., 19, 6309-6315 (2011). |
| 70. | Hilgeroth A., Hemmer M., Coburger C.: The Impact of the Induction of Multidrug Resistance Transporters in Therapies by Used Drugs: Recent Studies, Mini Rev. Med. Chem., 12, 1127-1134 (2012). |
| 71. | Tell V., Holzer M., Herrmann L., Mahmoud K. A., Schächtele C., Totzke F., Hilgeroth A.: Multitargeted Drug Development: Discovery and Profiling of Dihydroxy Substituted 1-Aza-9-oxafluorenes as Lead Compounds Targeting Alzheimer Disease Relevant Kinases, Bioorg. Med. Chem. Letters, 22, 6914-6918 (2012). |
| 72. | Tell V., Mahmoud K., Wichapong K., Schächtele C., Totzke F., Sippl W., Hilgeroth A.: Novel aspects in structure-activity relationships of profiled 1-aza-9-oxafluorenes as inhibitors of Alzheimer´s disease relevant kinases cdk1, cdk5 and gsk3β, Med. Chem. Commun., 3, 1413-1418 (2012). |
| 73. | Baumert C., Günthel M., Krawczyk S., Hemmer M., Wersig T., Langner A., Molnár J., Lage H., Hilgeroth A.: Development of Small-Molecule P-gp Inhibitors of the N-Benzyl 1,4-Dihydropyridine Type: Novel Aspects in SAR and Bioanalytical Evaluation of Multidrug Resistance (MDR) Reversal Properties, Bioorg. Med. Chem., 21, 166-177 (2013). |
| 74. | Telep El-Sayed M., Mahmoud K., Hilgeroth A.: Synthesis of β-Nitroamines via Classical Mannich and Aza-Henry Reactions, Curr. Org. Chem., 17, 1200-1224 (2013). |
| 75. | Hilgeroth A., Baumert C., Coburger C., Seifert M., Krawczyk S., Hempel C., Krug M., Molnár J., Lage H.: Novel Structurally Varied N-Alkyl 1,4-Dihydropyridines as ABCB1 Inhibitors: Structure-Activity Relationships, Biological Activity and First Bioanalytical Evaluation, Med. Chem., 9, 487-493 (2013). |
| 76. | Tell V., Hilgeroth A.: Recent developments of protein kinase inhibitors as potential AD therapeutics, Frontiers Cell. Neurosci., 7, doi: 10.3389/fncel.2013.00189 (2013). |
| 77. | El-Sayed M., Mahmoud K., Hilgeroth A.: Glacial acetic acid as efficient catalyst for simple synthesis of diindolylmethanes, Curr. Chem. Letters, 3, 7-14 (2014). |
| 78. | Mahmoud K. A., Krug M., Wersig T., Slynko I., Schächtele C., Totzke F., Sippl W., Hilgeroth A.: Discovery of 4-anilino α-carbolines as novel Brk inhibitors, Bioorg. Med. Chem. Letters, 24, 1948-1951 (2014). |
| 79. | Hilgeroth A., Tell V., Kramer S., Totzke F., Schächtele C.: Approaches to a Multitargeting Drug Development: First Profiled 3-Ethoxycarbonyl-1-aza-9-oxafluorenes Representing a Perspective Compound Class Targeting Alzheimer Disease Relevant Kinases CDK1, CDK5 and GSK-3β, Med. Chem., 10, 90-97 (2014). |
| 80. | Mahmoud K. A., Wersig T., Slynko I., Totzke F., Schächtele C., Oelze, M., Sippl W., Ritter C., Hilgeroth A.: Novel inhibitors of breast cancer relevant kinases Brk and HER2, Med. Chem. Commun., 5, 659-664 (2014). |
| 81. | Krawczyk S., Hilgeroth A.: HIV-1-Reverse-Transkriptase-Inhibitoren, Pharmakon, 2, 270-276 (2014). |
Buch-Beiträge
| 1. | Hilgeroth A.: Recent advances in the solid-state photochemistry of 1,4-dihydropyridines. In: Recent Res. Devel. Pure & Applied Chemistry, Vol. 3. Editor: S. G. Pandalai, Transworld Research Network, Trivandrum (India), pp. 153-159. |